Company: NCEL
Filing Date: 2025-07-01
Form Type: 425
Source: 0001213900-25-060355
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-07-01
Form: 425
Chunk 0
---
Filed by NLS Pharmaceutics Ltd. pursuant to

Rule 425 under the Securities Act of 1933, as amended

Subject Company: Kadimastem Ltd.

<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of July 2025

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐

CONTENTS</div>

Third Amendment to the Merger Agreement

On July 1, 2025, NLS Pharmaceutics Ltd. (the “Company”) entered into a fifth amendment (the “Fifth Amendment”) to the Agreement and Plan of Merger, dated November 4, 2024, and as previously amended on January 30, 2025, February 17, 2025, May 5, 2025, and on June 5, 2025 (the “Merger Agreement”) among the Company, Kadimastem Ltd. (“Kadimastem”) and NLS Pharmaceutics (Israel) Ltd. (collectively, the “Parties”).

Pursuant to the Fifth Amendment, the Parties agreed to extend the Merger Agreement’s termination date from June 30, 2025 to August 31, 2025 in order to complete the merger.

The Parties remain focused on and fully committed to aligning their efforts to completing the merger as soon as possible and with the utmost diligence. The Parties are actively working to fulfill all commitments related to the process and adhere to the requirements set forth by all regulatory agents.

Safe Harbor Statement

This Report of Foreign Private Issuer on Form 6-K contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company and Kadimastem are using forward-looking statements when they discuss the expected completion of the transaction. These forward-looking statements and their implications are